Modulation of microRNAs expression in hematopoietic stem cells treated with sodium butyrate in inducing fetal hemoglobin expression

References

• Ahmadvand M, Noruzinia M, Fard AD, Zohour MM, Tabatabaiefar MA, Soleimani M, et al. 2014. The role of epigenetics in the induction of fetal hemoglobin: a combination therapy approach. Int J Hematol Oncol Stem Cell Res. 8:9–14.
   PubMedGoogle Scholar
• Ahmadvand M, Norouzinia M, Soleimani M, Kaviani S, Abroun S, Dehghanifard A, Mahmoodinia MM. 2011. In vitro induction of the gamma globin gene in erythroid cells derived from cd133 + by thalidomide and sodium butyrate. Genetics. 9:2373–2378.
   Google Scholar
• Alijani S, Alizadeh S, Kazemi A, Khatib ZK, Soleimani M, Rezvani M, et al. 2014. Evaluation of the effect of miR-26b up-regulation on HbF expression in erythroleukemic K-562 cell line. Avicenna J Med Biotechnol. 6:53–56.
   PubMedGoogle Scholar
• Azzouzi I, Moest H, Winkler J, Fauchère JC, Gerber AP, Wollscheid B, et al. 2011. MicroRNA-96 directly inhibits γ-globin expression in human erythropoiesis. PLoS One. 6:e22838.
   PubMed Web of Science ®Google Scholar
• Bank A. 2006. Regulation of human fetal hemoglobin: new players, new complexities. Blood. 107:435–443.
   PubMed Web of Science ®Google Scholar
• Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R. 2009. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep. 42:493–499.
   PubMed Web of Science ®Google Scholar
• Cao H, Stamatoyannopoulos G, Jung M. 2004. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood. 103:701–709.
   PubMed Web of Science ®Google Scholar
• Chou YC, Chen RL, Lai ZS, Song JS, Chao YS, Shen CKJ. 2015. Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells. Mol Cell Biol. 35:2541–2545.
   PubMed Web of Science ®Google Scholar
• Constantoulakis P, Knitter G, Stamatoyannopoulos G. 1989. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood. 74:1963–1971.
   PubMed Web of Science ®Google Scholar
• Costa FC, Fedosyuk H, Neades R, Chazelle AM, Zelenchuk L, Fonteles AH, et al. 2013. A cell-based high-throughput screen for novel inducers of fetal hemoglobin for treatment of sickle cell disease, Cooley’s anemia and β-thalassemias. Blood. 122:925.
   Web of Science ®Google Scholar
• Dehghanifard A, Kaviani S, Noruzinia M, Soleimani M, Abroun S, Hajifathali A, et al. 2012. Synergistic effect of sodium butyrate and thalidomide in the induction of fetal hemoglobin expression in erythroid progenitors derived from cord blood CD133 + cells. Zahedan J Res Med Sci. 14:29–33.
   Google Scholar
• Dehghanifard A, Kaviani S, Noruzinia M, Soleimani M, Abroun S, Zonoubi Z, Ahmadvand M. 2011. Evaluation the effect of thalidomide and sodium butyrate on cord blood stem cell differentiation induction to erythroid lineage. Genetics. 9:2457–2461.
   Google Scholar
• Faller DV, Perrine SP. 1995. Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hematol. 2:109–117.
   PubMedGoogle Scholar
• Fard AD, Hosseini SA, Shahjahani M, Salari F, Jaseb K. 2013a. Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res 7:47–54.
   PubMedGoogle Scholar
• Fard AD, Kaviani S, Noruzinia M, Soleimani M, Abroun S, Chegeni R, et al. 2013b. Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. Lab Hematol 19:1–5.
   PubMedGoogle Scholar
• Fathallah H, Atweh GF. 2006. Induction of fetal hemoglobin in the treatment of sickle cell disease. ASH Educ Program 2006:58–62.
   Google Scholar
• Fibach E, Prasanna P, Rodgers G, Samid D. 1993. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood. 82:2203–2209.
   PubMed Web of Science ®Google Scholar
• Gabbianelli M, Testa U, Morsilli O, Pelosi E, Saulle E, Petrucci E, et al. 2010. Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica. 95:1253–1260.
   PubMed Web of Science ®Google Scholar
• Galanello R, Origa R. 2010. Review: beta-thalassemia. Orphanet J Rare Dis. 5:11.
   PubMed Web of Science ®Google Scholar
• Madigan C, Malik P. 2006. Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease. Expert Rev Mol Med. 8:1–23.
   Google Scholar
• Mathias LA, Fisher TC, Zeng L, Meiselman HJ, Weinberg KI, Hiti AL, Malik P. 2000. Ineffective erythropoiesis in β-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol. 28:1343–1353.
   PubMed Web of Science ®Google Scholar
• Minayi N, Alizadeh S, Dargahi H, Soleimani M, Khatib ZK, Tayebi B, et al. 2014. The effect of miR-210 up-regulation on proliferation and survival of mouse bone marrow derived mesenchymal stem cell. Int J Hematol Oncol Stem Cell Res. 8:15–23.
   PubMedGoogle Scholar
• Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. 1988. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 318:96–99.
   PubMed Web of Science ®Google Scholar
• Pace BS, Liu L, Li B, Makala LH. 2015. Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease. Exp Biol Med (Maywood). 240:1050–1064.
   PubMed Web of Science ®Google Scholar
• Panja A, Basu A. 2015. Pharmacogenomics of the drugs used for the treatment of thalassemia. J Cytol Histol. 6:360.
   Google Scholar
• Perrine S. 2011. Novel therapeutic agents for HbF induction: a new era for treatment of β thalassemia? Thalassemia Rep 1:e7.
   Google Scholar
• Perrine S, Miller B, Faller D, Cohen R, Vichinsky E, Hurst D, Lubin B, Papayannopoulou T. 1989. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia. Blood. 74:454–459.
   PubMed Web of Science ®Google Scholar
• Perrine SP. 2008. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr Ann. 37:339–346.
   PubMed Web of Science ®Google Scholar
• Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, et al. 1993. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med. 328:81–86.
   PubMed Web of Science ®Google Scholar
• Rees DC, Williams TN, Gladwin MT. 2010. Sickle-cell disease. Lancet. 376:2018–2031.
   PubMed Web of Science ®Google Scholar
• Rund D, Rachmilewitz E. 2005. β-Thalassemia. N Engl J Med. 353:1135–1146.
   PubMed Web of Science ®Google Scholar
• Sankaran VG. 2011. Targeted therapeutic strategies for fetal hemoglobin induction. ASH Educ Program 2011:459–465.
   Google Scholar
• Sankaran VG, Menne TF, Šćepanović D, Vergilio JA, Ji P, Kim J, et al. 2011. MicroRNA-15a and-16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA. 108:1519–1524.
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, et al. 2005. Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome. Br J Haematol. 131:378–388.
   PubMed Web of Science ®Google Scholar
• Stamatoyannopoulos G. 2005. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 33:259–271.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Rodgers GP. 2001. Pharmacologic modulation of fetal hemoglobin. Medicine. 80:328–344.
   PubMed Web of Science ®Google Scholar
• Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. 2006. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20:515–524.
   PubMed Web of Science ®Google Scholar
• Walker AL, Steward S, Howard TA, Mortier N, Smeltzer M, Wang YD, Ware RE. 2011. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. Blood. 118:5664–5670.
   PubMed Web of Science ®Google Scholar
• Weinberg RS, Ji X, Sutton M, Perrine S, Galperin Y, Li Q, et al. 2005. Butyrate increases the efficiency of translation of γ-globin mRNA. Blood. 105:1807–1809.
   PubMed Web of Science ®Google Scholar
• Wood W, Weatherall D, Clegg J. 1976. Interaction of heterocellular hereditary persistence of foetal haemoglobin with β thalassaemia and sickle cell anaemia. Nature. 264:247–249.
   PubMed Web of Science ®Google Scholar
• Zare M, Soleimani M, Mohammadian M, Akbarzadeh A, Havasi P, Zarghami N. 2014. Efficient biotechnological approach for lentiviral transduction of induced pluripotent stem cells. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi: 10.3109/21691401.2014.982804.
   PubMed Web of Science ®Google Scholar